Influenza vaccine supply, 2005–2006: did we come up short? by Bardenheier, Barbara H et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Influenza vaccine supply, 2005–2006: did we come up short?
Barbara H Bardenheier*1, Raymond Strikas†2, Allison Kempe†3, 
Shannon Stokley†1 and Jean Ellis†4
Address: 1National Center for Immunization and Respiratory Diseases, Coordinating Center for Infectious Diseases, Centers for Disease Control 
and Prevention, Atlanta, Georgia, USA, 2National Vaccine Program Office, Department of Health and Human Services, Washington, D.C., USA, 
3Department of Pediatrics, University of Colorado at Denver and Health Sciences Center and the Children's Outcomes Research Center, The 
Children's Hospital, Denver, Colorado, USA and 4Member Services and Business Development, Visiting Nurse Associations of America (VNAA), 
Boston, Massachusetts, USA
Email: Barbara H Bardenheier* - bfb7@cdc.gov; Raymond Strikas - Raymond.Strikas@psc.hhs.gov; Allison Kempe - Kempe.Allison@tchden.org; 
Shannon Stokley - SStokley@cdc.gov; Jean Ellis - JEllis@vnaa.org
* Corresponding author    †Equal contributors
Abstract
Background: Although total influenza vaccine doses available in the 2005/2006 influenza season
were over 80 million, CDC received many reports of delayed and diminished vaccine shipments in
October to November of 2005. To better understand the supply problems, CDC and partners
surveyed several health care professional groups.
Methods: Surveys were sent to representative samples of influenza vaccine providers including
pediatricians, internists, federally qualified health centers, visiting nurse organizations, and all 64
state and other health departments receiving federal immunization funds directly. In November and
December, 2005, providers were asked questions about their experience in ordering influenza
vaccine, sources where orders were placed, proportion of orders received, and referral of patients
to other vaccination sites.
Results: The number of providers surveyed (median: 154; range: 64 – 308) and response rates
(median: 62%; range: 51% – 77%) varied among groups. Less than half of the providers in most
groups placed a single order that was accepted (median: 31%; range: 8% – 53%), and most placed
multiple orders. Only 57% of federally qualified health centers and 60% of internists reported they
received at least 40% of their orders by the middle of December; the other provider groups
received a greater proportion of their orders. Most internists (80%) and federally qualified health
centers (54%) reported that they had referred priority group patients to other locations to receive
the influenza vaccine due to inadequate supplies. Vaccine providers who ordered only from Chiron
received a lower proportion of their orders than providers that ordered from another source or
ordered from multiple sources.
Conclusion: Most of the providers surveyed received only part of their orders by the middle of
December. Disruptions in receipt of influenza vaccine during the fall of 2005 were due primarily to
shortfalls in vaccine from Chiron and also due to delays and partial shipments from other
distributors.
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Background
Influenza is the most common vaccine-preventable dis-
ease in the United States, accounting for an average of
36,000 deaths and over 200,000 hospitalizations annu-
ally [1]. Vaccination is the cornerstone of prevention and
every fall about 80 million people are vaccinated over a 2–
3 month period in the United States [2]. Since 2000, how-
ever, problems with influenza vaccine production have
focused attention on vaccine manufacturing and distribu-
tion issues [3]. After the marked shortfall in supply which
characterized the 2004–2005 season, the projected supply
of inactivated influenza vaccine for the 2005 – 06 season
appeared adequate as of March 25, 2005. However, given
the uncertainty about the number of doses that would be
available and when they would be available, the Advisory
Committee for Immunization Practices (ACIP) encour-
aged implementation of a two-tiered distribution strategy
in which partial orders were first shipped to providers to
ensure priority group patients received vaccine early in the
season despite any decreases in production [4].
Although the total number of influenza vaccine doses ulti-
mately available in the 2005–2006 season exceeded 80
million, reports received by the Centers for Disease Con-
trol and Prevention (CDC) and others in October and
November, 2005, suggested that delays and diminished
shipments of vaccine left a number of providers and vac-
cine distributors without sufficient supply [5]. To better
understand the causes of the vaccine supply problems,
which immunization providers were affected and to what
extent, the CDC and partners surveyed several health care
professional groups. These data were presented to the
National Influenza Vaccine Summit on January 24, 2006,
to assist in addressing challenges and developing policy
[6].
Methods
Surveys were sent in November–December, 2005, to rep-
resentative samples of providers of influenza vaccine
within major national professional organizations. Provid-
ers sampled included pediatricians, internists, visiting
nurse organizations, providers in federally qualified
health centers, and state and other health departments
directly receiving federal immunization funds (grantees).
Results from other professional organizations surveyed
(ie, The American Association of Family Physicians, The
National Association of County and City Health Officers,
Community Vaccinator groups, Occupational Health
groups, the American Pharmacists Association, and the
American Hospital Association) are not presented because
of limited response rates.
Surveys were sent to a subset (283) of a sentinel network
of 431 pediatricians selected from a random sample of
2,500 members of the American Academy of Pediatricians
(AAP), representative of AAP membership overall with
respect to region, practice location, and practice setting.
These 283 physicians were surveyed by email; within the
sentinel physician network, physicians preferring to be
surveyed by email were not statistically significantly dif-
ferent from those who preferred to be surveyed by regular
mail. Those with a preference for email surveys were
selected for this study because of their rapid response rate.
Surveys were sent to a subset (308) of a sample of 438
internists selected from a random sample of 3,000 mem-
bers of the American College of Physicians (ACP), repre-
sentative of members with respect to region, practice
location, and practice setting. As above, these 308 physi-
cians were surveyed by email; within the sentinel physi-
cian network, physicians preferring to be surveyed by
email were not statistically significantly different from
those who preferred to be surveyed by regular mail.
The Visiting Nurse Associations of America (VNAA), one
of the community vaccinator organizations, surveyed all
154 member agencies via email. The survey for VNAA
members was web based. It was directed to all members
of the Visiting Nurse Associations of America. The recipi-
ent asked to complete the survey was the director of the
immunization program in the agency.
The National Association of Community Health Centers
(NACHC) randomly sampled 100 health centers from
919 health centers. Centers that were previously queried
in early 2005 about influenza vaccine (n = 44) and centers
for which there was no email address (n = 23) were
excluded from the sampling frame. The survey for
NACHC members was emailed to the contact of the ran-
domly selected 100 members, directed to Health Center
Colleague. They were asked to send the survey back to the
Chief Medical Officer of NACHC.
The CDC emailed surveys to immunization program
managers (grantees) in all 50 states, the District of Colum-
bia, the Federated States of Micronesia, the Marshall
Islands, Northern Marianas Islands (commonwealth),
Palau, and U.S. territories, including Guam, Puerto Rico,
American Samoa, and the Virgin Islands. Grantees were
asked to respond for all VFC and non-VFC vaccine orders.
Respondents participating in the provider surveys in all
groups were asked questions about their experience in
ordering influenza vaccine, sources where orders were
placed, proportion of orders received, if they had referred
any priority group patients to another location due to
inadequate vaccine supplies, and if they had encountered
any further problems. The cutoffs for orders received were
selected based on the expectation that ideally in mid-
November, providers expected to have received 80% orBMC Health Services Research 2007, 7:66 http://www.biomedcentral.com/1472-6963/7/66
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more of vaccine ordered, and 40% is the minimum we
judged to permit some vaccination programs to hold clin-
ics and vaccinate in offices. Sixty percent was an estimate
of Sanofi and Novartis vaccine delivery to customers
based on what the companies had projected to deliver by
the time of the survey earlier in the year.
The surveys of pediatricians and internists were conducted
as part of an ongoing study approved by the Colorado
Multi-Institutional Review Board. The other surveys in
this report were undertaken as a response to a public
health emergency and did not require a review by the
CDC's Institutional Review Board and consent was not
required.
Results
The number of providers contacted to be surveyed
(median: 154; range: 64 – 308) and corresponding
response rates (median: 62%; range: 51% – 77%) varied
among professional groups. [Additional file 1]
The majority of providers in all groups placed single or
multiple orders that were accepted (median: 67%; range:
52% – 90%). Very few providers among the groups
reported they had attempted to order but no orders were
accepted (median: 0%; range: 0% – 8%). Order not
accepted meant that the vaccine company or distributor
would not, or could not accept the order because the type
of vaccine ordered was not available from that supplier.
When orders were not accepted, more than half of
respondents in each group, except grantees (45%),
reported being put on a wait list.
More pediatricians (60%) than providers in other groups
(median: 17% range: 5%–39%) reported they ordered
FluZone® (Sanofi-Pasteur) directly from the manufacturer.
More members of the VNAA (86%) than providers in
other groups (median: 21%; range: 14%–42%) reported
they ordered FluZone® (Sanofi-Pasteur) from a vaccine
distributor. Similarly, more members of the VNAA (74%)
than providers in other groups (median: 16%; range: 8%–
47%) reported they ordered Fluvirin™ (Chiron) from a
vaccine distributor. Most pediatricians (62%) and mem-
bers of the VNAA (90%) ordered from ≥2 sources.
Only a little more than half of internists and members of
NACHC reported they received at least 40% of their order.
More grantees (86%) received >80% of their orders than
providers in other groups (median: 45%; range: 31%–
64%). Internists (n = 12 (11%)), pediatricians (n = 2
(1%)), and members of NACHC (n = 12 (19%)) who only
ordered from a Chiron distributor had received a lower
proportion of their orders by November than those who
ordered from a source other than Chiron.
At least half of the internists and members of NACHC
reported they referred priority group patients to another
location for influenza immunization due to inadequate
vaccine supplies; only 39% of pediatricians reported refer-
ring patients. The VNAA asked this question differently,
reporting that 41% of respondents experienced a shortage
of vaccine for priority patients between September 1 and
December 1, 2005. Among the members of NACHC,
internists, and pediatricians, those who received <41% of
their order were more likely to refer priority patients to
other providers (X2 p < 0.001).
All groups were asked to provide additional comments if
they had encountered further problems. Among those
who responded with comments (36% of pediatricians;
18% of internists; and 53% of VNAAs), providers reported
being unable to place orders, receiving partial or incom-
plete orders, and receiving orders very late. Respondents
also commented that uncertainty about the timing and
amount of vaccine they might receive not only limited
them in their ability to schedule appointments and/or
clinics but also prevented them from giving reliable infor-
mation to patients. In addition, providers reported frus-
tration because they perceived that non-medical
organizations were receiving vaccine for healthy individu-
als, while they were unable to receive vaccine for their
'sicker' priority group patients.
Discussion
Influenza vaccine supply steadily increased through the
1990's, but since 2000, vaccine shipments have been
either partly delayed or diminished below projections in
4 of 6 years. In the fall of 2005, we found that only a little
over half of internists and federally qualified health cent-
ers reported having received at least 40% of their orders
and at least half of providers in all groups, except pediatri-
cians, reported referring priority group patients to another
location for influenza immunization due to inadequate
vaccine supplies. Providers that ordered from multiple
sources or from sources other than Chiron distributors
reported receiving higher proportions of their orders. In
addition, some providers reported concerns that partial
shipments of vaccine spread out over the fall compro-
mised their ability to serve patients. Although the ACIP no
longer recommends tiering of prebooked orders (i.e.
orders placed in advance of availability) for priority
groups, [7] manufacturers will likely continue distributing
vaccine in partial shipments.
Providers who were unable to obtain an adequate supply
of vaccine felt the uncertainty of 'if and when' they might
receive vaccine not only limited their ability to schedule
appointments and/or clinics, but also prevented them
from communicating reliable information to their
patients, thus creating a breach of provider-patient trust.BMC Health Services Research 2007, 7:66 http://www.biomedcentral.com/1472-6963/7/66
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Participants in the National Influenza Vaccine Summit
echoed this frustration among their constituents [8].
One limitation of this study is that the sampling schemes
varied among provider groups. Also, response bias among
survey respondents is possible because those with prob-
lems receiving the vaccine might have been more anxious
to reply. Response rates were greater than 50%, which is
satisfactory for health care providers. These data provide a
comprehensive view of influenza vaccine supply ordering
and distribution patterns in the United States in late 2005.
Conclusion
By the end of the 2005–2006 season, 81.8 million doses
were distributed, only slightly less than the maximum
number of doses ever distributed, 83 million doses in
2003. Nevertheless the season did not unfold smoothly
both because some Chiron customers did not receive vac-
cine and because partial shipments may have contributed
to delays. In response to the influenza vaccine distribu-
tion and delay problems of this season, members of the
National Influenza Vaccine Summit recommended strate-
gies for improvement, including improved communica-
tions in vaccine ordering and distribution, reconsidering
partial vaccine shipment policies, enhanced government
roles, limited vaccine prioritization (tiering) to increase
vaccine utilization, and improved ability to track ordered
and shipped vaccine. Implementing these actions, cou-
pled with the expectations of over 100 million doses of
influenza vaccine for 2006–2007, should help the nation
move towards achieving the Healthy People 2010 objec-
tives for influenza vaccination and reduce the burden of
influenza disease.
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